Patient P-01511

Synthetic patientNBL-101 · Day 118 · 35–44 · F · baseline S14Open companion preview

Therapy response

Improving

Tolerance

Improving

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 54 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 57 GI-04 recommended — GI Support Protocol GI-04
Day 58 Patient accepted — Started GI-04 in the companion
Day 63 ME-01 recommended — Monitoring Escalation ME-01
Day 64 Patient accepted — Started ME-01 in the companion
Day 66 GI symptom burden −20% vs expected — GI Support Protocol GI-04
Day 67 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 72 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 54.

Primary contributors, last 14 days

GI instability+34
Inflammatory activity+19
Nutritional resilience-19
Toxicity-9
Treatment adherence+7

What helped?

GI Support Protocol GI-04Day 57
Result: symptom burden −20%
Monitoring Escalation ME-01Day 63
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

63%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 72 and rising
- WearableSleep 6.1 h, below personal baseline
Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 63
- WearableHRV 38 ms, trending down
Autonomic recovery ↓65
- WearableResting HR 72 bpm
- Wearable3,156 steps/day
- WearableShort sleep window
Butyrate / short-chain fatty acid production ↓20
- Daily logFibre intake low in recent food logs

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Intermediate metabolizer
Expected exposure

Microbiome

Shannon diversity 2.8 · butyrate capacity 46/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 40 ms
Sleep: 6.1 h
Steps: 3,920
Resting HR: 69 bpm

Daily log: GI score 72, nutritional resilience 38, adherence 52.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01842	48%	S14	NP-02	improved	55
P-01668	46%	S14	GI-04	no change	58
P-01647	45%	S14	GI-04	improved	64
P-01339	44%	S14	GI-04	improved	54
P-01614	44%	S14	GI-04	improved	53
P-01692	43%	S14	NP-02	improved	49
P-01473	42%	S14	GI-04	improved	51
P-01393	41%	S14	GI-04	improved	53
P-01438	41%	S14	GI-04	improved	56
P-01507	41%	S10	GI-04	improved	63
P-01716	41%	S14	GI-04	improved	56
P-01465	40%	S14	NP-02	improved	56